Risks

Negative interest coverage and a long cash conversion cycle increase refinancing and working-capital pressure, leaving AVNS less resilient than larger medtech peers with stronger earnings conversion.

Inventory days above 140 and DSO above 52 suggest slower cash realization, which can constrain flexibility versus peers with tighter distributor and hospital collections.

A negative net debt-to-EBITDA reading indicates earnings are not covering leverage cleanly, so any demand softness could impair balance-sheet optionality more than for better-capitalized peers.

The current ratio is solid, but AVNS still faces more liquidity sensitivity than peers with stronger free-cash-flow generation and less dependence on working-capital release.

Opportunities

A current ratio above 2.4 and quick ratio above 1.4 provide near-term liquidity headroom, supporting AVNS better than more levered medtech peers during demand volatility.

Low debt-to-equity versus many healthcare equipment peers can preserve strategic flexibility if operating performance stabilizes, improving relative positioning on capital structure.

If inventory normalization continues, the unusually high cash conversion cycle could unwind, releasing cash faster than peers with already efficient working-capital profiles.

AVNS may benefit from steady elective-procedure and hospital supply demand, where established product positioning can support more stable volumes than more discretionary medtech categories.

Overall Score

AVNS has acceptable liquidity and relatively low balance-sheet leverage, but weak earnings coverage and inefficient working capital keep peer-relative risk elevated, while cash-release potential and stable healthcare demand provide moderate upside.